Table I.
Patient/disease characteristics and correlations between ESR and various clinicopathological variables.
| Variables | n | ESR (mm/h), median (range) | HR (95% CI) | P-value |
|---|---|---|---|---|
| No. of patients | 139 | 22 (2–122) | ||
| Age (years) | 1.001 (0.985–1.018) | 0.162 | ||
| <50 | 64 | 20.5 (2–122) | ||
| ≥50 | 75 | 23 (3–83) | ||
| Sex | 1.017 (0.999–1.035) | 0.006 | ||
| Male | 87 | 19 (2–122) | ||
| Female | 52 | 30 (5–83) | ||
| Site of lesion | 1.005 (0.984–1.026) | 0.652 | ||
| Axial | 69 | 22 (3–70) | ||
| Extremities | 58 | 19.5 (2–83) | ||
| Histopathology | 0.978 (0.953–1.003) | 0.005 | ||
| Nodular | 24 | 27 (10–70) | ||
| Others | 74 | 19.5 (2–83) | ||
| Clark's level | 1.012 (0.979–1.047) | 0.280 | ||
| I–III | 19 | 16 (3–63) | ||
| IV–V | 83 | 21 (5–83) | ||
| Breslow's thickness, mm | 1.016 (0.981–1.051) | 0.398 | ||
| <2 | 20 | 18.5 (3–62) | ||
| ≥2 | 85 | 21 (3–83) | ||
| Mitotic rate, n/mm2 | 1.011 (0.986–1.036) | 0.387 | ||
| ≤3 | 47 | 20 (3–83) | ||
| >3 | 50 | 21 (7–83) | ||
| Ulceration | 1.028 (0.999–1.059) | 0.115 | ||
| Absent | 38 | 20 (3–52) | ||
| Present | 62 | 22 (3–83) | ||
| Neurotropism | 1.013 (0.953–1.075) | 0.690 | ||
| Absent | 58 | 20.5 (3–83) | ||
| Present | 3 | 25 (22–40) | ||
| Vertical growth phase | 0.999 (0.925–1.079) | 0.988 | ||
| Absent | 3 | 15 (10–42) | ||
| Present | 60 | 20 (3–83) | ||
| Lymphovascular invasion | 1.026 (0.994–1.060) | 0.107 | ||
| Absent | 72 | 19.5 (3–66) | ||
| Present | 15 | 26 (5–83) | ||
| Tumor-infiltrating lymphocytes | 1.008 (0.978–1.039) | 0.599 | ||
| Absent | 23 | 16 (3–83) | ||
| Present | 70 | 21.5 (3–83) | ||
| Regression | 1.012 (0.987–1.039) | 0.350 | ||
| Absent | 61 | 20 (3–66) | ||
| Present | 28 | 21 (7–83) | ||
| BRAF (V600E) mutation | 0.972 (0.931–1.015) | 0.171 | ||
| Negative | 12 | 27 (7–96) | ||
| Positive | 15 | 22 (6–63) | ||
| Hemoglobin level | 0.953 (0.931–0.975) | <0.001 | ||
| Low | 36 | 35.5 (10–122) | ||
| Normal | 98 | 18 (2–83) | ||
| Serum lactate dehydrogenase | 1.033 (1.012–1.055) | 0.003 | ||
| Normal | 109 | 21 (2–83) | ||
| High | 24 | 34 (11–122) | ||
| Lymph node metastasis | 1.023 (0.994–1.054) | 0.188 | ||
| No | 35 | 18 (2–52) | ||
| Yes | 68 | 22 (5–83) | ||
| No. of lymph node metastasis | 1.028 (0.996–1.060) | 0.078 | ||
| 1 | 37 | 21 (5–51) | ||
| ≥2 | 30 | 22 (5–83) | ||
| Metastatic stage (M1) | 1.044 (1.022–1.066) | <0.001 | ||
| No | 99 | 18 (2–75) | ||
| Yes | 40 | 31.5 (2–122) | ||
| Stage of metastatic disease | 0.989 (0.965–1.014) | 0.401 | ||
| M1a-b | 14 | 37 (15–96) | ||
| M1c | 26 | 31.5 (2–122) | ||
| Response to chemotherapy | 0.987 (0.959–1.016) | 0.390 | ||
| No | 20 | 38 (15–122) | ||
| Yes | 14 | 31.5 (6–83) |
ESR, erythrocyte sedimentation rate; HR, hazard ratio; CI, confidence interval.